IRADIMED CORPORATION reported $86M of revenue over the trailing twelve months, +11% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $86M (to Q2 2026). Net income: $23M, trailing twelve months to Q2 2026. Free cash flow: $25M, trailing twelve months to Q2 2026. Operating margin: 32%, trailing twelve months to Q2 2026.

IRMDIRADIMED CORPORATION

Healthcare

$87.53+26% 1Y

$87.53

$67.7752 weeks$104.87

IRMD as reported

IRADIMED CORPORATION reported $86M of revenue over the trailing twelve months, +11% on the year before. 10 reported series are charted on this page, each one as filed.

$86M

Revenue, trailing twelve months · to Q2 2026 · +11% against the twelve months before

Net income: $23M
Net income · +12% year on year · trailing twelve months to Q2 2026
Free cash flow: $25M
Free cash flow · +77% year on year · trailing twelve months to Q2 2026
Operating margin: 32%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for IRMD, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$86M	+11%	Q2 2026
Net income	$23M	+12%	Q2 2026
EPS	$1.79	+10%	Q2 2026
Gross margin	76%	n/a	Q2 2026
Operating margin	32%	n/a	Q2 2026
Net margin	27%	n/a	Q2 2026
ROE	23%	n/a	Q2 2026
ROA	20%	n/a	Q2 2026
Free cash flow	$25M	+77%	Q2 2026
P/E	48.9	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.